Zosyn is a drug owned by Wyeth Pharmaceuticals Llc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 14, 2023. Details of Zosyn's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8133883 | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(2 years ago) |
Expired
|
| US7915229 | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(2 years ago) |
Expired
|
| US6900184 | Compositions containing pipercillin and tazobactam useful for injection |
Apr, 2023
(2 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zosyn's patents.
Latest Legal Activities on Zosyn's Patents
Given below is the list of recent legal activities going on the following patents of Zosyn.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 15 Apr, 2024 | US8133883 |
| Maintenance Fee Reminder Mailed Critical | 30 Oct, 2023 | US8133883 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 05 Aug, 2022 | US7915229 |
| Change in Power of Attorney (May Include Associate POA) Critical | 24 Jun, 2022 | US8133883 |
| Email Notification Critical | 24 Jun, 2022 | US8133883 |
| Correspondence Address Change Critical | 23 Jun, 2022 | US8133883 |
| Email Notification Critical | 23 Jun, 2022 | US7915229 |
| Change in Power of Attorney (May Include Associate POA) Critical | 23 Jun, 2022 | US7915229 |
| Correspondence Address Change Critical | 22 Jun, 2022 | US7915229 |
| Change in Power of Attorney (May Include Associate POA) Critical | 21 Jun, 2022 | US6900184 |
US patents provide insights into the exclusivity only within the United States, but Zosyn is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zosyn's family patents as well as insights into ongoing legal events on those patents.
Zosyn's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zosyn's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 14, 2023 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zosyn Generic API suppliers:
Piperacillin Sodium; Tazobactam Sodium is the generic name for the brand Zosyn. 13 different companies have already filed for the generic of Zosyn, with Sandoz having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zosyn's generic
How can I launch a generic of Zosyn before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Zosyn's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Zosyn's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Zosyn -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 2.25 g/vial 3.375 g/vial 4.5 g/vial | |||||
| 12 g/1.5 g per vial (pharmacy bulk) | 06 Dec, 2011 | 1 | 29 Oct, 2014 | 14 Apr, 2023 | Eligible |
| 36 mg/4.5 g per vial (pharmacy bulk) | 1 | 15 Sep, 2009 | 14 Apr, 2023 | Eligible |
Alternative Brands for Zosyn
Zosyn which is used for treating bacterial infections., has several other brand drugs in the same treatment category and using the same active ingredient (Piperacillin Sodium; Tazobactam Sodium). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Abbvie |
| |||||
| Baxter Hlthcare Corp |
| |||||
| Cubist Pharms Llc |
| |||||
| Cumberland |
| |||||
| Hikma |
| |||||
| Lg Chem Ltd |
| |||||
| Pfizer |
| |||||
| Pf Prism Cv |
| |||||
| Rempex |
| |||||
| Shionogi Inc |
| |||||
Apart from brand drugs containing the same ingredient, some generics have also been filed for Piperacillin Sodium; Tazobactam Sodium, Zosyn's active ingredient. Check the complete list of approved generic manufacturers for Zosyn
About Zosyn
Zosyn is a drug owned by Wyeth Pharmaceuticals Llc. It is used for treating bacterial infections. Zosyn uses Piperacillin Sodium; Tazobactam Sodium as an active ingredient. Zosyn was launched by Wyeth Pharms in 1993.
Approval Date:
Zosyn was approved by FDA for market use on 22 October, 1993.
Active Ingredient:
Zosyn uses Piperacillin Sodium; Tazobactam Sodium as the active ingredient. Check out other Drugs and Companies using Piperacillin Sodium; Tazobactam Sodium ingredient
Treatment:
Zosyn is used for treating bacterial infections.
Dosage:
Zosyn is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INJECTABLE | Discontinued | INJECTION |
| EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INJECTABLE | Discontinued | INJECTION |
| EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INJECTABLE | Discontinued | INJECTION |
| EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INJECTABLE | Discontinued | INJECTION |